Nicox Analyst Coverage Initiated by Kepler Cheuvreux
November 25, 2020 – release at 8:00 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Kepler Cheuvreux, a leading independent European financial services company, ranked the first independent equity broker in Europe (Institutional Investor 2020), has initiated equity research coverage of Nicox.
The financial report by Kepler Cheuvreux, released on November 25, 2020, is available on the website www.keplercheuvreux.com under « Research Public Access ».
About Nicox
Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.
For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Bryan, Garnier & Co Victor Floc’h Paris, France
Cantor Fitzgerald Louise Chen New York, U.S.
H.C. Wainwright & Co Yi Chen New York, U.S.
Kepler Cheuvreux Damien Choplain Paris, France
Oppenheimer & Co Hartaj Singh New York, U.S.
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
[email protected]
United States & Europe
LifeSci Advisors, LLC
Mary-Ann Chang
T +44 7483 284 853
[email protected]
France
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
[email protected]
Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2019’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which are available on Nicox’s website (www.nicox.com).
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99